Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Stockholders' Equity [Abstract]

Schedule of stock-based compensation

	For the Three Months Ended March 31,
	2023		2022
Research and development	$	11,772	$	28,808
General and administrative		325,829		427,615
Total	$	337,601	$	456,423

Schedule of stock options outstanding and exercisable

						Weighted Average
	Stock Options					Exercise Price				Fair Value		Contractual Life		Aggregate Intrinsic
	Outstanding			Exercisable		Outstanding		Exercisable		Vested		(Years)		Value
Balance – December 31, 2022		317,857			194,853	$	44.53	$	38.53	$	38.53		6.99	$	-
Granted		-			-		-		-		-		-		-
Exercised		-			-		-		-		-		-		-
Cancelled		(64,863	)		-		-		-		-		-		-
Balance – March 31, 2023		252,994			195,192	$	46.03	$	40.21	$	40.21		6.63	$	-

Schedule of stock option activity

Grant Price				Weighted Average Exercise		Total		Number		Weighted Average
From		To		Price		Outstanding		Exercisable		Remaining Contractual Term
$	6.00	$	60.60	$	35.90		220,259		146,796	6.58 years
$	63.00	$	138.00	$	83.16		21,301		36,962	4.07 years
$	159.00	$	181.20	$	172.14		11,434		11,434	4.84 years
					Totals		252,994		195,192

Schedule of warrant activity

						Weighted Average
	Warrants					Exercise Price				Fair Value		Contractual Life		Aggregate Intrinsic
	Outstanding			Exercisable		Outstanding		Exercisable		Vested		(Years)		Value
Balance – December 31, 2022		1,178,169			1,178,169	$	30.67	$	30.67	$	17.83		3.41	$	-
Granted		-			-		-		-		-		-		-
Exercised		-			-		-		-		-		-		-
Cancelled		(854	)		-		-		-		-		-		-
Balance – March 31, 2023		1,177,315			1,177,315	$	30.66	$	30.66	$	17.79		3.16	$	-